Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04142931 | Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors | unknown | Phase 1 | 30 | Dr. Ronnie ShapiraOTHER_GOV | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04809779 | PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC(NeoPD1TNBC) | unknown | Phase 2 | 49 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER |
| 1 |
| Mar 22, 2021 |
| clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | withdrawn | N/A | 0 | Jaroslaw HepelOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT03577743 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 54 | Assiut UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03135782 | Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy | completed | N/A | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02324088 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer(PEGASE07) | completed | Phase 3 | 174 | UNICANCEROTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT03698383 | Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 15 | Korean Cancer Study GroupOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03946683 | Cyberknife for Early Stage Breast Cancer | completed | N/A | 26 | NYU Langone HealthOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04756921 | 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response | completed | — | 30 | Biyun Wang, MDOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04300829 | Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients(CICA-RT) | unknown | Phase 3 | 248 | Centre Leon BerardOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03102307 | Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD) | completed | — | 548 | Kliniken Essen-MitteOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | terminated | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT01796041 | Intraoperative Imaging of Breast Cancer With Indocyanine Green(ICG) | completed | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer(SYSUCC-007) | terminated | Phase 3 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT01004744 | Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | completed | N/A | 10 | Columbia UniversityOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT02632071 | ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | completed | Phase 1 | 17 | Columbia UniversityOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 18 | Kathy MillerOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT04676997 | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02375958 | PCA062 in pCAD-positive Tumors. | completed | Phase 1 | 47 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT04549584 | Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer(NEO-SMART) | terminated | — | 3 | Seoul National University HospitalOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04669522 | Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer(PSY-ONC TNBC) | unknown | — | 50 | Pius-Hospital OldenburgOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04609540 | Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC | unknown | — | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 16, 2020 | clinicaltrials |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT04582955 | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03295695 | PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04639271 | Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis | unknown | Phase 2 | 100 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03365895 | Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)(CIPN) | completed | N/A | 17 | University of ArizonaOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | terminated | Phase 2 | 32 | GTxINDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT03618017 | The ConnectedCancerCare Pilot Study (CCC)(CCC) | completed | N/A | 66 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Nov 3, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04607473 | ABUS for Early-stage Breast Cancer | unknown | N/A | 675 | Samsung Medical CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer(BATON-BC) | terminated | Phase 2 | 30 | AVEO Pharmaceuticals, Inc.INDUSTRY | 10 | Oct 27, 2020 | clinicaltrials |
| NCT03617341 | Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer | unknown | — | 200 | Yonsei UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT02576106 | Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy(CRYOSE01) | completed | N/A | 22 | Centre Leon BerardOTHER | 1 | Oct 22, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 24, 2021source: clinicaltrials